川寧生物(301301.SZ):與金珵科技簽署戰略合作協議
格隆匯2月22日丨川寧生物(301301.SZ)公佈,2024年2月22日,伊犁川寧生物技術股份有限公司(簡稱“公司”“川寧生物”或“甲方”)與上海金珵科技有限公司(簡稱“金珵科技”或“乙方”)簽署了《伊犁川寧生物技術股份有限公司與上海金珵科技有限公司戰略合作協議》,鑑於雙方各自的優勢,雙方經友好協商決定實行優勢互補、合作共贏發展戰略,達成本協議。
雙方同意建立戰略合作關係,充分發揮各方在各自領域的優勢,整合各類資源,就川寧生物抗生素中間體發酵產業的優化升級、利用 AI輔助合成生物學研發及合作開發新產品等方面開展合作,將人工智能與川寧生物現有產業結合,儘快形成新質生產力,以全面提升川寧生物的生產方式和生產效率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.